Dianthus Therapeutics, Inc.
NASDAQ:DNTHBiotechnology
-$1.03 today
- Market cap
- $4.73B
- Beta
- 0.07
- P/E (TTM)
- -343.0
- EPS (TTM)
- -$0.24
Volume 0.84M
Average 0.82M
DNTH Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Dianthus Therapeutics, Inc.NASDAQ: DNTH
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization growth accelerates
Q2 FY2026 depreciation & amortization of $107K rose 8.1% year over year, ahead of the -11.0% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 40.8% from the prior quarter. Over 3 fiscal years it compounded at +42.8% a year.
Context
- Depreciation & amortization amounted to 21.0% of revenue in FY2025, up 14.4 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +8.1% holds above the trailing-twelve-month pace of -11.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 428K USD
- Year-over-year change
- +3.9%
- 4-year CAGR
- -32.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 428K | +3.9% |
| FY2024 | 2024-12-31 | 412K | +16.1% |
| FY2023 | 2023-12-31 | 355K | +141.5% |
| FY2022 | 2022-12-31 | 147K | -92.7% |
| FY2021 | 2021-12-31 | 2.02M | — |
Depreciation & Amortization vs competitors
How DNTH compares with its peers on the latest reported figures
- DNTH's LTM Jun 2026 depreciation & amortization of $379K is the 8th highest of the 10 companies compared; the peer median is $2.42M.
- Its year-over-year change of -11.0% is the 8th highest of 10, against a peer median of +6.6%.
- Depreciation & amortization amounts to 19.9% of revenue for DNTH, versus a peer median of 20.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $3.08M | +50.1% | +151.3% | — | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $2.65M | -20.7% | +140.9% | 35.9% |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $2.64M | +6.6% | +30.9% | — |
| LTM Mar 2026 | $2.43M | +1.2% | +1.2% | 1.0% | |
| LTM Mar 2026 | $2.42M | +13.8% | +13.3% | 136.2% | |
| FY2025 | $704K | +6.7% | -11.9% | 1100.0% | |
| LTM Jun 2026 | $536K | +89.4% | — | — | |
| LTM Jun 2026 | $379K | -11.0% | +42.8% | 19.9% | |
| LTM Sep 2026 | $378K | -10.0% | +28.4% | 5.3% | |
| LTM Mar 2026 | $362K | -25.1% | +1.9% | 0.7% | |
| Peer median (excluding DNTH) | $2.42M | +6.6% | +20.8% | 20.6% | |
Competitors are the stored peer set for DNTH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.48M | 6.42M | 2.83M | 6.24M | 2.04M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 1.48M | 6.42M | 2.83M | 6.24M | 2.04M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 12.61M | 29.38M | 32.84M | 83.11M | 145.64M |
| Selling, General & Admin | 1.96M | 6.74M | 18.16M | 24.99M | 34.33M |
| Operating Expenses | 14.56M | 36.12M | 51M | 108.1M | 179.97M |
| Depreciation & Amortization | 2.02M | 147K | 355K | 412K | 428K |
| EBITDA | (11.09M) | (28.33M) | (43.2M) | (84.56M) | (161.91M) |
| EBITDA Margin | -751.3% | -441.5% | -1528.7% | -1356.2% | -7952.3% |
| Operating Income | (13.09M) | (29.71M) | (48.17M) | (101.86M) | (177.93M) |
| Operating Margin | -886.6% | -462.9% | -1704.7% | -1633.7% | -8739.3% |
| Interest Income | 100K | 1.15M | 4.76M | 17.37M | 16.12M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (23K) | 1.23M | 4.62M | 16.9M | 15.6M |
| Income Before Tax | (13.11M) | (28.48M) | (43.56M) | (84.97M) | (162.34M) |
| Pre-Tax Margin | -888.1% | -443.8% | -1541.2% | -1362.8% | -7973.3% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (13.11M) | (28.48M) | (43.56M) | (84.97M) | (162.34M) |
| Net Margin | -888.1% | -443.8% | -1541.2% | -1362.8% | -7973.3% |
| EPS (Basic) | (3.82) | (7.60) | (8.45) | (2.55) | (4.20) |
| EPS (Diluted) | (3.82) | (7.60) | (8.45) | (2.55) | (4.20) |
| Weighted Avg Shares | 3.43M | 3.75M | 5.15M | 33.31M | 37.79M |
| Weighted Avg Shares (Diluted) | 3.43M | 3.75M | 5.15M | 33.31M | 37.79M |
Dianthus Therapeutics, Inc.
NASDAQ:DNTH
Intrinsic Alpha fair value
Locked
Current Price
$83.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.